Reference is made to the stock exchange notice published on 24 August 2018 regarding publication of a prospectus and with further information regarding a subsequent offering with gross proceeds of up to NOK 20 million directed towards eligible shareholders (the "Subsequent Offering").

 

The subscription period for the Subsequent Offering ends today, 10 September 2018 at 16.30 hours (CEST). Subscription rights that are not utilized within the end of the subscription period will lapse automatically and hold no value.

 

For further information, please contact:

Jon Olav Ødegård, CFO of Hofseth BioCare ASA

Mob: +47 936 32 966

E-mail: joo@hofsethbiocare.no

 

About Hofseth BioCare ASA:

HBC is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBC's objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.

 

Hofseth BioCare's headquarters are located in Ålesund, Norway with branches in Oslo, Chicago, Mumbai, Palo Alto and Tokyo. HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at www.hofsethbiocare.com and www.facebook.com/hofsethbiocare

 

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.